{"transactions":[{"id":1824912,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-21T21:10:29.000Z","date":"2023-07-19","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.72,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-043140","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919123043140/doc4.xml","form_type":"4"}},{"id":1904435,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:44:37.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":2.8,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001640455-23-000111","document":"wf-form4_168320066591032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000111/wf-form4_168320066591032.xml","form_type":"4"}},{"id":1904434,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:44:37.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.27,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000111","document":"wf-form4_168320066591032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000111/wf-form4_168320066591032.xml","form_type":"4"}},{"id":1904433,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:44:37.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.58,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000111","document":"wf-form4_168320066591032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000111/wf-form4_168320066591032.xml","form_type":"4"}},{"id":1904432,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:44:37.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":4.46,"underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-23-000111","document":"wf-form4_168320066591032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000111/wf-form4_168320066591032.xml","form_type":"4"}},{"id":1904431,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:44:37.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13350,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":7.92,"underlying":"Common Stock","underlying_shares":13350},"source":{"system":"sec-edgar","filing":"0001640455-23-000111","document":"wf-form4_168320066591032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000111/wf-form4_168320066591032.xml","form_type":"4"}},{"id":1904430,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:44:37.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16260,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":9.56,"underlying":"Common Stock","underlying_shares":16260},"source":{"system":"sec-edgar","filing":"0001640455-23-000111","document":"wf-form4_168320066591032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000111/wf-form4_168320066591032.xml","form_type":"4"}},{"id":1904429,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-04T07:44:37.000Z","date":"2023-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75880,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":4.06,"underlying":"Common Stock","underlying_shares":75880},"source":{"system":"sec-edgar","filing":"0001640455-23-000111","document":"wf-form4_168320066591032.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000111/wf-form4_168320066591032.xml","form_type":"4"}},{"id":1904428,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-04T07:44:37.000Z","date":"2023-05-03","kind":"other","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent (\"Merger Sub\"), dated as of March 26, 2023 (the \"Merger Agreement\"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of May 3, 2023 (the \"Effective Time\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the merger agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes and (ii) one contingent value right."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the merger agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes and (ii) one contingent value right."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001640455-23-000111","document":"wf-form4_168320066591032.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000111/wf-form4_168320066591032.xml","form_type":"4"}},{"id":2220131,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-28T21:07:14.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":20000,"derivative":{"exercise_price":2.8,"expiration_date":"2032-06-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001640455-22-000073","document":"wf-form4_165646481976787.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045522000073/wf-form4_165646481976787.xml","form_type":"4"}},{"id":2224265,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T21:38:51.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.54,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038734","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919122038734/doc4.xml","form_type":"4"}},{"id":2647985,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T23:00:42.000Z","date":"2021-06-29","kind":"exercise","acquired":false,"shares":19763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8126},"source":{"system":"sec-edgar","filing":"0000899243-21-027012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027012/doc4.xml","form_type":"4"}},{"id":2647984,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T23:00:42.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":18698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction occurred prior to the IPO and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":18698,"derivative":{"exercise_price":6.11,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":18698},"source":{"system":"sec-edgar","filing":"0000899243-21-027012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027012/doc4.xml","form_type":"4"}},{"id":2647983,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-07-01T23:00:42.000Z","date":"2021-03-11","kind":"grant","acquired":true,"shares":19763,"price":5.06,"value":100000.78,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction occurred prior to the IPO and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":19763,"derivative":{"underlying":"Common Stock","underlying_shares":8126},"source":{"system":"sec-edgar","filing":"0000899243-21-027012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027012/doc4.xml","form_type":"4"}},{"id":2647982,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-01T23:00:42.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":74794,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction occurred prior to the IPO and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of June 5, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":74794,"derivative":{"exercise_price":0.3,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":74794},"source":{"system":"sec-edgar","filing":"0000899243-21-027012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027012/doc4.xml","form_type":"4"}},{"id":2647981,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T23:00:42.000Z","date":"2021-06-29","kind":"exercise","acquired":true,"shares":8126,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering (\"IPO\") without payment of additional consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":164034,"source":{"system":"sec-edgar","filing":"0000899243-21-027012","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000089924321027012/doc4.xml","form_type":"4"}},{"id":2658793,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T16:34:40.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":7.27,"expiration_date":"2031-06-18","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-21-000108","document":"wf-form4_162439406001292.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045521000108/wf-form4_162439406001292.xml","form_type":"4"}},{"id":2937906,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"exercise","acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 21, 2020."}],"balance_after":0,"derivative":{"exercise_price":15.78,"expiration_date":"2029-05-20","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937905,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"exercise","acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 17, 2019."}],"balance_after":0,"derivative":{"exercise_price":25.98,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937904,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"exercise","acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 17, 2018."}],"balance_after":0,"derivative":{"exercise_price":14.35,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937903,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"exercise","acquired":false,"shares":31764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on May 5, 2019."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2026-05-04","underlying":"Common Stock","underlying_shares":31764},"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937902,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":21336,"price":54.33,"value":1159184.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.10 to $54.48, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937901,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":45450,"price":53.69,"value":2440210.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.09 to $54.08, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price."}],"balance_after":26336,"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937900,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":21978,"price":52.52,"value":1154284.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.02 to $53.00, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 17, 2020 at each separate price."}],"balance_after":71786,"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937899,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":19000,"price":15.78,"value":299820.0,"ownership":{"direct":true},"balance_after":93764,"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937898,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":19000,"price":25.98,"value":493620.0,"ownership":{"direct":true},"balance_after":74764,"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937897,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":19000,"price":14.35,"value":272650.0,"ownership":{"direct":true},"balance_after":55764,"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":2937896,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-18T21:29:06.000Z","date":"2020-12-17","kind":"exercise","acquired":true,"shares":31764,"price":18,"value":571752.0,"ownership":{"direct":true},"balance_after":36764,"source":{"system":"sec-edgar","filing":"0001209191-20-064425","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120064425/doc4.xml","form_type":"4"}},{"id":3091891,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-02T19:35:40.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original Form 4 filed on June 29, 2020 erroneously reported 13,550 shares of common stock subject to the stock option. This amendment is being filed to disclose the correct number of shares subject to the reported stock option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":7.58,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-20-000089","document":"wf-form4a_159373292481119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000089/wf-form4a_159373292481119.xml","form_type":"4/A","original_submission_date":"2020-06-29"}},{"id":3097556,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-29T19:34:40.000Z","date":"2020-06-26","kind":"grant","acquired":true,"shares":13550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":13550,"derivative":{"exercise_price":7.58,"expiration_date":"2030-06-26","underlying":"Common Stock","underlying_shares":13550},"source":{"system":"sec-edgar","filing":"0001640455-20-000073","document":"wf-form4_159347364711098.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045520000073/wf-form4_159347364711098.xml","form_type":"4"}},{"id":3104322,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-19T20:46:26.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":20.72,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-20-037970","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919120037970/doc4.xml","form_type":"4"}},{"id":3487759,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T23:00:36.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its non-employee director compensation policy. The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service."}],"balance_after":15000,"derivative":{"exercise_price":24.68,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-19-036004","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465919036004/a4.xml","form_type":"4"}},{"id":3491389,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-13T10:31:12.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":15700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2020 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":15700,"derivative":{"exercise_price":4.46,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":15700},"source":{"system":"sec-edgar","filing":"0001640455-19-000055","document":"wf-form4_156043625682291.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045519000055/wf-form4_156043625682291.xml","form_type":"4"}},{"id":3515322,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-22T20:35:33.000Z","date":"2019-05-21","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 21, 2019 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":15.78,"expiration_date":"2029-05-20","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-19-032084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919119032084/doc4.xml","form_type":"4"}},{"id":3551025,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-23T16:15:22.000Z","date":"2019-04-23","kind":"other","acquired":false,"shares":80500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC (\"Mereo\"), Mereo US Holdings Inc., Mereo Mergerco One Inc. (\"Merger Sub\") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the \"Merger\"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the \"Merger Consideration\") for each share of the Issuer's stock that they own."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-19-010983","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000089924319010983/doc4.xml","form_type":"4"}},{"id":3883965,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T18:09:18.000Z","date":"2018-06-22","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.55,"expiration_date":"2028-06-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-18-029840","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118029840/doc1.xml","form_type":"4"}},{"id":3886143,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-21T17:17:12.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":13550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in equal quarterly installments during the four quarters following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":13550,"derivative":{"exercise_price":7.92,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":13550},"source":{"system":"sec-edgar","filing":"0001640455-18-000085","document":"wf-form4_152961581571578.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045518000085/wf-form4_152961581571578.xml","form_type":"4"}},{"id":3890837,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-19T00:44:25.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan.  The vesting commencement date (the \"Vesting Commencement Date\") of the option is the grant date.  All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service."}],"balance_after":15000,"derivative":{"exercise_price":21.64,"expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-18-040887","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465918040887/a4.xml","form_type":"4"}},{"id":3924066,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-05-21T16:56:52.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 17, 2018 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":25.98,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-18-031692","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919118031692/doc4.xml","form_type":"4"}},{"id":4026911,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-28T16:45:06.000Z","date":"2018-02-26","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/6 of the shares subject thereto on each monthly anniversary of January 3, 2018, subject to the Reporting Person's continued service to the Issuer as Executive Chairman through each such vesting date."}],"balance_after":120000,"derivative":{"exercise_price":2.29,"expiration_date":"2028-02-26","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001140361-18-010828","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118010828/doc1.xml","form_type":"4"}},{"id":4026910,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-28T16:45:06.000Z","date":"2018-02-26","kind":"grant","acquired":true,"shares":70500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of Restricted Stock Units (\"RSUs\").  The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof."}],"balance_after":80500,"source":{"system":"sec-edgar","filing":"0001140361-18-010828","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036118010828/doc1.xml","form_type":"4"}},{"id":4269358,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-30T20:02:23.000Z","date":"2017-06-29","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option award was granted under Voyager Therapeutics, Inc.'s 2015 Stock Option and Incentive Plan pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy and will vest in full upon the first anniversary of the grant, subject to Mr. Karsen's continued service on the Board of Directors."}],"balance_after":15000,"derivative":{"exercise_price":9.06,"expiration_date":"2027-06-29","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-17-042938","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465917042938/a4.xml","form_type":"4"}},{"id":4289681,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-07T18:18:45.000Z","date":"2017-06-05","kind":"purchase","acquired":true,"shares":10000,"price":3.4588,"value":34588.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades in prices ranging from $3.340937 to $3.50, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001140361-17-024400","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117024400/doc1.xml","form_type":"4"}},{"id":4293043,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-05T12:01:19.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":5000,"price":11.985,"value":59925.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-17-037518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117037518/doc4.xml","form_type":"4"}},{"id":4295571,"issuer":{"id":158190,"kind":"organization","name":"OncoMed Pharmaceuticals Inc","symbol":"OMED"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-02T17:21:53.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.3,"expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-17-023637","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1302573/000114036117023637/doc1.xml","form_type":"4"}},{"id":4311833,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-19T21:08:03.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 18, 2017 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":19000,"derivative":{"exercise_price":14.35,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001209191-17-033980","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652130/000120919117033980/doc4.xml","form_type":"4"}},{"id":4471189,"issuer":{"id":15754,"kind":"organization","name":"Jounce Therapeutics, Inc.","symbol":"JNCE"},"owners":[{"id":111219,"kind":"person","name":"KARSEN PERRY A","position":1,"cik":"0001260573","reported_name":"KARSEN PERRY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-02T17:03:59.000Z","date":"2017-02-01","kind":"purchase","acquired":true,"shares":5000,"price":16,"value":80000.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001104659-17-006179","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640455/000110465917006179/a4.xml","form_type":"4"}}]}